GlassScriptPhysician profile
Javed Nisar Sadiq
NPI 1609194703
$4,383.10
in general payments reported to CMS, 2019-2025
27 companies · $1,199 in 2025
The $1,199 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $412 · 2020: $128 · 2021: $422 · 2022: $715 · 2023: $558 · 2024: $950 · 2025: $1,199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,706.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,706.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,830.64 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $362.27 | 2019-2025 | Xifaxan |
| Redhill Biopharma INC. | $280.06 | 2020-2023 | Aemcolo, Movantik, Talicia |
| Gilead Sciences, INC. | $260.55 | 2019-2025 | |
| Janssen Biotech, INC. | $221.98 | 2024-2025 | Tremfya, Stelara, Simponi Aria |
| Pfizer INC. | $202.23 | 2022-2024 | |
| Ardelyx, INC. | $152.19 | 2022-2023 | Ibsrela |
| Shionogi INC | $148.61 | 2019 | |
| Pentax of America, INC. | $132.75 | 2022 | |
| Qol Medical, LLC | $131.31 | 2023-2025 | Sucraid, Sucraid |
| Intercept Pharmaceuticals, INC. | $110.87 | 2020-2025 | Ocaliva |
| Celgene Corporation | $85.67 | 2023-2024 | Zeposia |
| Genzyme Corporation | $60.07 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $54.67 | 2019-2021 | |
| Madrigal Pharmaceuticals | $52.49 | 2025 | Rezdiffra |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $47.81 | 2024-2025 | Vegzelma, Zymfentra |
| Ironwood Pharmaceuticals, INC | $47.02 | 2019-2024 | |
| Ipsen Biopharmaceuticals, INC | $34.43 | 2025 | Iqirvo |
| Lilly USA, LLC | $27.40 | 2024 | Omvoh |
| Alcresta Therapeutics, INC. | $24.82 | 2024 | Relizorb |
| Evoke Pharma, INC. | $22.08 | 2023 | Gimoti |
| Novo Nordisk INC | $20.05 | 2025 | Wegovy |
| Alnylam Pharmaceuticals INC. | $17.13 | 2021 | |
| Phathom Pharmaceuticals, INC. | $15.39 | 2025 | Voquezna |
| Mallinckrodt Hospital Products INC. | $15.10 | 2023 | Terlivaz |
| Braintree Laboratories, INC. | $13.02 | 2023 | Sutab |
| Allergan, INC. | $12.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Javed Sadiq listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.